Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof

A kit for the preparation and delivery of a pharmaceutical aerosol for pulmonary administration comprising a dispersed liquid phase and a continuous gas phase;

• wherein the dispersed liquid phase
• (a) comprises aqueous droplets comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-);
• or pharmaceutically acceptable salt thereof;
• wherein
• OctG is (S)-2-aminodecanoic acid;
• DPro is D-proline;
• sodium chloride;
• (b) has a mass median diameter from about 1.5 μm to about 5 μm;
• and
• (c) has a droplet size distribution having a geometrical standard deviation from about 1.2 to about 1.7;
• and
• wherein the kit comprises a nebulizer and a liquid composition comprising a concentration within a range from about 4 mg/mL to about 100 mg/mL of the active compound;
• or pharmaceutically acceptable salt thereof;
• or
• wherein the dispersed liquid phase
• (a) comprises aqueous droplets comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-);
• or pharmaceutically acceptable salt thereof;
• wherein
• OctG is (S)-2-aminodecanoic acid;
• DPro is D-proline;
• sodium chloride;
• (b) has a mass median diameter from about 1.5 μm to about 5 μm;
• and
• (c) has a droplet size distribution having a geometrical standard deviation from about 1.2 to about 1.7;
• and
• wherein the kit comprises a nebulizer and a solid pharmaceutical composition for preparing the liquid composition, wherein the solid composition comprises the active compound cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-);
• or pharmaceutically acceptable salt thereof;
• and wherein the solid composition is dissolvable or dispersible in an aqueous liquid solvent, and wherein the liquid composition comprises a concentration within a range from about 4 mg/mL to about 100 mg/mL of the active compound;
• or pharmaceutically acceptable salt thereof;
• for use in a method for the prevention, management or treatment of diseases or conditions of the lungs being mediated by or resulting from human neutrophil elastase activity in a subject.